KMKazuhiro Murai

Kazuhiro Murai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kazuhiro Murai has a total of 195 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B

    by Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto, et al.

    Background and Aim: Although nucleos(t)ide analog (NUC) therapy reduces hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients, HCC can develop despite viral suppression. Identifying predictive biomarkers of HCC during NUC therapy remains clinically important. This study aimed to identify novel biomarkers by proteomic analysis of serum extracellular vesicle (EV) proteins in CHB patients receiving NUC therapy. Methods: We enrolled 242 CHB patients treated with NUCs for over one year, with serum HBV DNA < 3.0 log IU/mL, no prior HCC, and available stored serum samples. Proteomic analysis of serum EV proteins was carried out to identify candidate biomarkers, followed by validation of their serum levels using enzyme‐linked immunosorbent assay (ELISA). Results: The median age was 55 years; 144 were male. During a median follow‐up of 10.1 years, 44 patients (18.2%) developed HCC. Five candidate EV proteins were identified: fibulin‐3, VCAM‐1, fibronectin, vWF, and FGFBP2. In univariate Cox analysis of serum levels of candidate EV proteins measured by ELISA, fibulin‐3 and VCAM‐1 were identified as significant predictive factors. In multivariate analysis, male sex, GGT, AFP, fibulin‐3, and the FIB‐4 index were independent predictors, whereas VCAM‐1 was not. A cutoff value for fibulin‐3 was set at 10.8 μg/mL. HCC incidence was significantly higher in patients with fibulin‐3 ≥ 10.8 μg/mL and in those with ≥ 3 of five identified risk factors. The 10‐year cumulative HCC incidence was 0% versus 37.2% in patients with 0 versus ≥ 3 risk factors. Conclusion: Serum fibulin‐3 is a novel biomarker predictive of HCC in CHB patients undergoing NUC therapy.

  • Open Access

    Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy

    by Satoshi Shigeno, Takahiro Kodama, Kazuhiro Murai, Emi Sometani, Kentaro Yasuda, Yuki Tahata, Akira Nishio, Satoshi Tanaka, Masanori Miyazaki, Kazuyoshi Ohkawa, et al.

    Background: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure—defined by hepatitis B surface antigen (HBsAg) loss—is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. Methods: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcriptomic and functional assays. In a retrospective cohort, we evaluated serum interleukin-1β (IL-1β) as a predictor of HBsAg decline during long-term follow-up. Results: scRNA-seq revealed that CD14 + CD16 − classical monocytes in the HBsAg-declining group expressed significantly higher levels of IL-1β, along with genes involved in antigen presentation and phagocytosis. In the validation cohort, IL-1β expression in circulating CD14 + classical monocytes was also significantly higher in the declining group. Ex vivo stimulation assays demonstrated that recombinant HBsAg induced IL-1β production in monocytes, with stronger responses in the declining group. Recombinant IL-1β suppressed HBsAg secretion from HBV-producing HepG2.2.15 cells in vitro in a dose-dependent manner. In a longitudinal cohort, elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71. Multivariate analysis confirmed IL-1β as an independent predictor. Conclusions: Monocyte-derived IL-1β is linked to HBsAg decline during NA therapy and may serve as both a predictive biomarker and a potential therapeutic target to achieve functional cure.

  • Open Access

    Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

    by Chinatsu Nishioka, Yuki Tahata, Kazuki Maesaka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, et al.

    Background and Aim: The optimal second-line therapy following first-line atezolizumab plus bevacizumab remains unascertained. In this study, we compared second-line durvalumab plus tremelimumab with lenvatinib after first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (uHCC). Methods: In this retrospective, open-label, non-randomized comparative study, we analyzed real-world data derived from a prospectively registered observational cohort of patients with uHCC who received durvalumab plus tremelimumab (the Dur/Tre group, n = 14) or lenvatinib (the Len group, n = 67) as second-line therapy after first-line atezolizumab plus bevacizumab. Tumor response was assessed using the RECIST criteria version 1.1. Progression-free survival (PFS), overall survival (OS), adverse events (AEs), and changes in the albumin–bilirubin (ALBI) score were compared between the groups. Results: The objective response and disease control rates were 7.7% and 15.4% in the Dur/Tre group and 23.3% and 76.7% in the Len group, respectively. The median PFS was 1.7 vs. 4.2 months (p < 0.001) and median OS was 5.3 vs. 14.0 months (p = 0.047) in the Dur/Tre and Len groups, both significantly favoring lenvatinib. Multivariable analysis showed that lenvatinib treatment was an independent predictor of longer PFS, and a neutrophil-to-lymphocyte ratio ≥ 3 was an independent predictor of worse OS. Grade ≥ 3 AEs were more frequent with lenvatinib than with durvalumab plus tremelimumab (70.1% vs. 21.4%; p = 0.002). At week 4, the ALBI score was maintained with durvalumab plus tremelimumab (−2.30 to −2.21; p = 0.318) but worsened with lenvatinib (−2.36 to −1.97; p < 0.001). Conclusions: After first-line atezolizumab plus bevacizumab, second-line lenvatinib achieved superior disease control and longer survival than durvalumab plus tremelimumab. However, grade ≥ 3 AEs were more frequent with lenvatinib than with durvalumab plus tremelimumab. Careful AE management is therefore important when selecting therapy for individual patients.


  • Open Access

    Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

    by Yu Sato, Takahiro Kodama, Kazuki Maesaka, Machiko Kai, Kazuhiro Murai, Yuki Tahata, Yoshinobu Saito, Tasuku Nakabori, Kazuyoshi Ohkawa, Satoshi Tanaka, et al.

    Background: Atezolizumab plus bevacizumab (Atez/Bev) has become the first-line therapy for unresectable hepatocellular carcinoma (HCC). However, reliable biomarkers to predict therapeutic response remain lacking. Methods: We conducted a high-throughput plasma proteomic screen using the Olink proximity extension assay to identify predictive biomarkers in 78 patients with unresectable HCC treated with Atez/Bev. Validation was performed in an independent cohort of 89 patients. Tumorous expression of the lead candidate, carbonic anhydrase 9 (CA9), was examined using transcriptomic and single-cell analyses. Functional studies were performed in a syngeneic mouse model using Car9-overexpressing hepatoma cells, treated with anti-programmed death-ligand 1/vascular endothelial growth factor antibodies, with or without a CA9 inhibitor. Results: High plasma CA9 levels were significantly associated with poor objective response rate, disease control rate, progression-free survival, and overall survival in both discovery and validation cohorts. Multivariable analysis confirmed CA9 as an independent predictor of treatment resistance and poor outcomes. Tumorous CA9 expression correlated strongly with circulating CA9 and was restricted to malignant cells. In vivo, tumors overexpressing Car9 showed resistance to Atez/Bev therapy, characterized by reduced CD8+T cell infiltration, suppressed cytotoxic gene expression, enrichment of M2-like macrophages, and pro-angiogenic signaling. The addition of a CA9 inhibitor reversed resistance and restored antitumor efficacy of Atez/Bev in this model. Conclusions: Tumor-derived circulating CA9 is a predictive biomarker and functional driver of resistance to Atez/Bev therapy in HCC. Targeting CA9 may enhance therapeutic response.


  • Open Access

    Impact of Treatment Response to Anticoagulant Therapy on Liver‐Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

    by Atsushi Maeda, Yuki Tahata, Hayato Hikita, Hisashi Ishida, Takayuki Yakushijin, Masanori Nakahara, Kazuyoshi Ohkawa, Fumihiko Nakanishi, Sadaharu Iio, Ryotaro Sakamori, et al.

    Aim: The effect of treatment response to anticoagulant therapy on prognosis of patients with cirrhosis and portal vein thrombosis (PVT) remains unclear. Methods: Forty‐one patients with cirrhosis and first PVT treated with intravenous anticoagulant therapy between January 2015 and April 2018 at 10 Japanese hospitals were included. Treatment response was defined based on change in size of PVT after anticoagulant therapy as the following: complete response (CR, 0%), partial response (PR, ≤ 50%), stable disease (SD, 51%–100%), and progressive disease (PD, ≥ 101%). CR and PR were combined as the effective group and SD and PD formed as the ineffective group. Results: The median age was 69 years, and 56% of the patients had Child–Pugh class B. Overall, 5 (12%) achieved CR, 22 (54%) achieved PR, 12 (29%) had SD and 2 (5%) had PD. During a median follow‐up of 31.8 months from the date of assessment of treatment response, 17 patients died. The overall survival rates at 1‐ and 3‐year were 82.5% and 65.1%, respectively. In the multivariate analysis, the model for end‐stage liver disease‐Na score was significantly associated with overall survival, whereas treatment response was not significant. Twenty‐five patients experienced liver‐related events with hospitalization, and the 3‐year cumulative rate of liver‐related events was 63.9%. In the multivariate analysis, treatment response was significantly associated with liver‐related events. The 3‐year cumulative rates of liver‐related events were 56.7% and 75.5% in the effective and ineffective groups, respectively ( p = 0.008). Conclusions: Among patients with cirrhosis, treatment response to anticoagulant therapy for PVT correlated with the incidence of liver‐related hospitalization events.

  • Open Access

    Genome-wide CRISPR screen identifies ACSL3 as a regulator of lipotoxicity and progression of MASLD

    by Yuta Myojin, Takahiro Kodama, Ryo Takahashi, Hideharu Nagasawa, Yasuteru Kondo, Kosuke Yusa, Tomomi Yoshida-Hashidate, Hideo Shindou, Kunimaro Furuta, Kazuhiro Murai, et al.

    Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction–associated steatohepatitis, are highly prevalent and lack effective pharmacotherapies. Hepatocellular lipotoxicity—driven by the accumulation of saturated fatty acids (eg, palmitate)—promotes disease progression; however, the determinants of hepatocyte susceptibility remain incompletely defined. Methods: We performed a genome-wide CRISPR-Cas9 loss-of-function screening to identify the regulators of palmitate-induced lipotoxicity. The top candidates were validated using genetic perturbation and pharmacological inhibition. Lipid handling, endoplasmic reticulum/oxidative stress, apoptosis, and lipogenic transcriptional programs were also quantified. Human MASLD liver tissues were analyzed for ACSL3 expression in relation to histology and aminotransferases. Single-cell and spatial transcriptomics were used to localize ACSL3 expression and the associated pathway signatures in metabolic dysfunction–associated steatohepatitis. Results: The screen recovered established mediators (CASPASE-8, AGPAT9, RNF213) and identified ACSL3 as a novel determinant of hepatocyte survival under lipotoxic stress. Genetic deletion or pharmacological inhibition of ACSL3 renders hepatocytes resistant to palmitate-induced apoptosis and endoplasmic reticulum stress, accompanied by reduced lipid-droplet accumulation, decreased incorporation of saturated fatty acids into neutral lipids and phospholipids, and blunted induction of lipogenic programs. In human MASLD, hepatic ACSL3 expression positively correlated with histological severity and aminotransferase levels. Single-cell transcriptomics localized ACSL3 predominantly to hepatocytes in advanced metabolic dysfunction–associated steatohepatitis displaying oxidative and endoplasmic reticulum stress signatures, whereas spatial transcriptomics showed ACSL3-high hepatocyte regions enriched for apoptotic and inflammatory pathways and spatially coupled to macrophage-rich and plasma cell–rich niches. Conclusions: ACSL3 is a central regulator of lipotoxic hepatocyte injury and MASLD progression, mechanistically linking lipid-droplet biogenesis to apoptosis and inflammatory niche formation. These data suggest that ACSL3 is a promising therapeutic target and support further translational studies to evaluate ACSL3 modulation in steatotic liver disease.


  • Open Access

    Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage

    by Akiyoshi Shimoda, Kazuhiro Murai, Hayato Hikita, Satoshi Minami, Takayuki Miyake, Shinji Kuriki, Emi Sometani, Jihyun Sung, Satoshi Shigeno, Yuichiro Higuchi, et al.

    Background and aim: Hepatitis B surface antigen (HBsAg) is associated with hepatocellular carcinoma risk and immune exhaustion and contributes to hepatitis B virus (HBV) persistence. Current anti-HBV treatments have a limited ability to reduce HBsAg levels. This study aimed to identify FDA-approved drugs capable of reducing HBsAg levels and explore the underlying mechanisms. Methods: A total of 1134 FDA-approved compounds were screened at 9.9 μM for 7 days using HepG2.2.15.7 cells, which contain an integrated HBV genome. HBsAg in the supernatant and cell viability were assessed. Compounds whose viability was reduced by >1 SD were excluded. Compounds whose HBsAg concentration decreased by >1.5 SD were selected and validated at 0.5 and 5 μM. We evaluated the HBsAg-reducing effect of the final candidate compounds using HBV-infected primary human hepatocytes (HepaSH cells) derived from chimeric TK-NOG mice and investigated the underlying mechanism responsible for the reduction in HBsAg. Results: After 126 cytotoxic compounds were excluded, the HBsAg levels of the 6 candidates decreased by >1.5 SD. Ethacridine and auranofin significantly reduced the level of HBsAg at both 5 and 0.5 μM. In HepaSH cells, only auranofin decreased the level of HBsAg. Auranofin did not affect the HBe antigen, HBV-DNA, or pregenomic RNA, nor did it reduce the level of intracellular HBsAg, as determined by Western blotting. Transmission electron microscopy revealed more vesicles in auranofin-treated HepaSH cells than in control cells. Immunofluorescence analysis of HepaSH cells treated with auranofin revealed increased Galectin-3 expression and colocalization of HBsAg with Galectin-3, which was consistent with lysosomal damage, compared with those of the untreated controls. Conclusion: Auranofin, an FDA-approved antirheumatic agent, reduces HBsAg secretion via lysosomal damage.


  • Open Access

    Comparison of outcomes of second-line durvalumab plus tremelimumab and lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

    by Chinatsu Nishioka, Yuki Tahata, Kazuki Maesaka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, et al.

    Background and Aim: The optimal second-line therapy following first-line atezolizumab plus bevacizumab (Atezo/Beva) remains unascertained. This study compared second-line durvalumab plus tremelimumab (Dur/Tre) with lenvatinib (Len) after first-line Atezo/Beva in unresectable hepatocellular carcinoma (uHCC). Methods: This prospectively registered cohort study analyzed patients with uHCC who received Dur/Tre (n = 14) or Len (n = 67) as second-line therapy after first-line Atezo/Beva. Tumor response was assessed by RECIST version 1.1. Progression-free survival (PFS), overall survival (OS), adverse events (AEs), and changes in the albumin–bilirubin (ALBI) score were compared. Results: The objective response rate and disease control rate were 7.7% and 15.4% in the Dur/Tre group, and 23.3% and 76.7% in the Len group, respectively; median PFS was 1.7 vs. 4.2 months (p < 0.001) and median OS was 5.3 vs. 14.0 months (p = 0.047) in the Dur/Tre and Len groups, both significantly favoring Len. Multivariable analysis showed that Len treatment and neutrophil-to-lymphocyte ratio ≥3 were independent predictors of longer PFS and worse OS, respectively. Grade ≥3 AEs were more frequent with Len than with Dur/Tre (70.1% vs. 21.4%; p = 0.002). At week 4, the ALBI score did not worsen with Dur/Tre (−2.30 to −2.21; p = 0.318) but worsened with Len (−2.36 to −1.97; p < 0.001). Conclusions: After first-line Atezo/Beva, second-line Len achieved superior disease control and longer survival than Dur/Tre. However, grade ≥ 3 AEs were more frequent with Len than with Dur/Tre, and careful management of AEs is essential when choosing therapy for individual patients.


  • Open Access

    Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

    by Yuta Myojin, Hayato Hikita, Yuki Tahata, Kenji Fukumoto, Seiya Kato, Yoichi Sasaki, Shusuke Kumazaki, Atsunori Tsuchiya, Masaru Enomoto, Daiki Miki, et al.

    Background and Aims: Although direct‐acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates, the long‐term outcomes of patients with hepatitis C virus (HCV)‐related cirrhosis remain variable. Growth differentiation factor 15 (GDF15), a stress‐induced cytokine, has emerged as a potential biomarker for liver disease progression. This study aimed to evaluate the prognostic value of serum GDF15 levels in predicting hepatocellular carcinoma (HCC), hepatic decompensation, and mortality in patients with HCV‐related cirrhosis. Methods: We retrospectively analyzed 196 patients with HCV‐related cirrhosis who achieved SVR at 18 Japanese institutions. Serum GDF15 levels were measured at baseline (BL) and 24 weeks posttreatment (p24w). A previously validated cutoff of 1.75 ng/mL was applied. The clinical outcomes included HCC occurrence, hepatic decompensation, and all‐cause mortality. Results: During a median follow‐up of 46.2 months, 75 patients developed HCC, 28 experienced hepatic decompensation, and 25 died. Hepatic decompensation occurred significantly less frequently in the BL GDF15‐low group. Importantly, no deaths occurred in the GDF15‐low group, whereas the 5‐year survival rate in the GDF15‐high group was 71.7%. Similar trends were observed for GDF15 levels at p24w. In the overall cohort, GDF15 was not significantly associated with incident HCC; among HCC‐naïve patients, a nonsignificant trend toward lower 3‐year HCC incidence was observed in the GDF15‐low group. Conclusions: Serum GDF15 is a promising prognostic biomarker for post‐SVR outcomes in patients with HCV‐related cirrhosis. Its ability to predict decompensation and mortality through a validated cutoff supports its use for risk stratification and long‐term management in patients with chronic liver disease.


  • Open Access

    The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs

    by Kazuhiro Murai, Hayato Hikita, Ryoko Yamada, Yuki Nishimura, Masanori Miyazaki, Hisashi Ishida, Atsushi Hosui, Ryotaro Sakamori, Nobuyuki Tatsumi, Kazuyoshi Ohkawa, et al.

    Background and Aim: Nucleos(t)ide analogs (NUCs) are used in the treatment of chronic hepatitis B (CHB). It is still uncertain whether the risk of incident hepatocellular carcinoma (HCC) continues beyond 5 or 10 years after the initiation of NUC treatment. We aimed to elucidate this in CHB patients receiving long‐term NUC treatment.Methods: This was a multicenter, observational study that included patients who began NUC treatment between July 2000 and March 2019; patients were retrospectively enrolled up to March 2019 and followed up until August 2024.Results: Among 737 CHB patients (156 with cirrhosis) who started NUC treatment, 147 developed HCC during a median follow‐up period of 144.2 months. The 5‐, 10‐, and 15‐year cumulative HCC rates were 11.2%, 18.4%, and 23.1%, respectively. Independent risk factors for subsequent HCC occurrence included older age, male sex, cirrhosis, low platelet count, low ALT levels, and high γ‐GTP levels at NUC initiation. After 5 years, the risk factors were cirrhosis, high γ‐GTP levels, and high AFP levels, whereas after 10 years, they were cirrhosis and diabetes. Landmark analysis revealed that the 5‐year cumulative HCC incidence was 8.1% at 5 years and 5.8% at 10 years after NUC initiation. In noncirrhotic patients, cumulative HCC incidence at 5 years was 5.8%, whereas 5‐year cumulative incidences starting at 5 and 10 years were 4.1% and 4.8%, respectively, remaining stable over time.Conclusion: The risk of HCC persists long after NUC initiation. In noncirrhotic patients, the risk remains stable more than 10 years after NUC treatment initiation.